GBT Reports Second Quarter 2018 Results

Wednesday, August 15, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NET REVENUES UP BY 42%. ADJUSTED EBITDA SURGED BY 65%.

MONTEVIDEO, Uruguay, Aug. 14, 2018 /PRNewswire/ -- Biotoscana

Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 2Q18.

 

HIGHLIGHTS

Gross revenues for 2Q18 grew 33% in constant currency, marking BRL 981M LTM.

Net revenues for 2Q18 increased by 42% in constant currency, marking BRL 882M LTM.

Gross profit up 39% in 2Q18, in constant currency. Gross margin of 53% in line with prior quarters.

Adjusted EBITDA increased by 65% in constant currency vs. 2Q17.  Adjusted EBITDA margin came to 25% in 2Q18, improving 381 bps vs. 2Q17, marking BRL 226M LTM compared to BRL 203M in 2Q17 LTM.

Net income totaled BRL 20M in 2Q18, from a loss of BRL 3M in 2Q17. Adjusted net income up 380% from 2Q17, reaching BRL 32M in 2Q18.

Lenvima launching ahead of schedule and improving clinical profile with new indications submitted. Cresemba and Zevtera approved in Peru.

Extended partnership with Gilead into the Andean region, with revenues stream in 2Q18.

 

Contacts: Melissa Angelini ir@grupobiotoscana.com +55-11-5090-5927

Cision View original content:http://www.prnewswire.com/news-releases/gbt-reports-second-quarter-2018-results-300697212.html

SOURCE Grupo Biotoscana



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store